Company ProfilePremium

BYON Co., Ltd.

Company Profile Analysis

Ticker: 032980.KQ주식회사 바이온

ESOMAR 23 Corporate BadgeISO Certifications Badge
BYON Co., Ltd. - Company showcase

Year Founded & Workforce

1983

17 Employees

BYON Co., Ltd. logo

BYON Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

BYON Co., Ltd. Overview

BYON Co., Ltd. is a 43-year-old Korean corporate shell with a long history of business reinvention. It began as Seoul Electron, an electronics company, and later operated as Polyvision, which made PVC advertising banners, tarpaulins and flooring. From 2016 it repositioned under the BYON name as a "bio-medical" company. In practice, most of its revenue came from trading high-pressure-processed red ginseng raw materials, supported by a minority stake in stem-cell developer MiraeCell Bio. From late 2023, a change of control to CTM Co., Ltd. pushed the business into unrelated industrial assets: hydraulic machinery (CM Tech), a minority stake in Gwangjin Sanjeon, fuel sales and ship components. Repeated failed control transfers, disclosure violations, and criminal complaints against management followed. The company recorded net losses every year from FY2015 to FY2025, received a disclaimer audit opinion for FY2025, and was delisted from KOSDAQ on 1 July 2026.


Company's own description (latest available investor material)

The most recent investor-relations presentation found is the May 2021 IR deck [S18]. It described BYON as a KOSDAQ-listed small or medium enterprise whose main businesses were cosmetics manufacturing and sales, plus distribution of health functional food raw materials. The deck organised operations into three divisions: Bio-medical, at roughly 82% of FY2020 separate revenue; Cosmetics, at roughly 9%; and Auto parts, at roughly 1%. The deck made five main points:

Bio-medical: The core activity was processing ginseng into red ginseng raw materials using high-pressure technology. Supply came from a farm partner in Geumsan under a December 2015 alliance with Baeknyeon F&G. The output was sold as an input for cosmetics, pharmaceuticals and health supplements. Customers included large domestic companies and pharmaceutical firms; the deck names Amorepacific and Ilyang Pharmaceutical [S18].

Stem cells: BYON held 23.53% of affiliate MiraeCell Bio (미래셀바이오), which was developing stem-cell therapies and preparing for a KOSDAQ technology-special listing [S18].

Medical devices: BYON planned to build a GMP facility for contract manufacturing of stem-cell-applied wound dressings and in-vitro diagnostic devices. For this it acquired roughly 940 m² in the Gwangmyeong medical cluster [S18].

Financial profile: Management stressed a "no-borrowing" stance: a debt ratio of 19.13% and current ratio of 347.90% at FY2020 (consolidated) [S18].

Third-party profiles based on later filings describe a broader and more fragmented business. Stockopedia reported that the company ran eight reporting segments: bio-medical, cosmetics, health supplements, fuel sales, ship components, hydraulic motors, automotive parts, and others [S25]. Simply Wall St and Morningstar describe stem-cell cell-therapy development and cardiomyocyte commercialisation, supply of health functional food ingredients, and cosmetics, cosmetic containers and auxiliary materials [S13a][S26].

Independent characterisation

Based on the filing trail, BYON is best understood as a listed holding vehicle whose operating mix followed whoever controlled it, not as a focused operating company:

1983–2015 (Seoul Electron / Polyvision era): industrial products. These included advertising banners ("banner flex"), tarpaulins and PVC flooring, made at a plant in Ochang, Chungcheongbuk-do [S23][S24].

  • 2016–2023 (BYON "bio" era, under the Kim Byung-joon management): a trading-led red-ginseng raw-material business. Smaller contributions came from cosmetics (including the STEMELIN brand launched in 2022), auto-parts trading, and furniture or beauty-device trading. The bio narrative depended on equity stakes in MiraeCell Bio and other affiliates rather than on in-house R&D. Disclosed R&D spend never exceeded ₩1.3 billion a year.

2024–2026 (CTM era, under CEO Ryu Jin-hyung): the company bought industrial assets connected to its new controlling shareholder. It took 28% of Gwangjin Sanjeon in March 2024 [S10] and 100% of CM Tech, a heavy-equipment parts and hydraulic machinery maker, in May 2024 [S17]. By 2025, Pharmatimes reported that most revenue came from fuel and ship-parts sales, while bio-medical revenue had fallen from ₩9.6 billion in 2021 to ₩0.2 billion in 2024 [S6].

Business model and revenue model

DimensionAssessment
Product vs. service vs. subscription vs. licensingAlmost entirely product sales and merchandise trading. The 2018–2021 segment tables classify bio-medical, cosmetics and auto-parts revenue as merchandise (상품) sales, not manufactured goods [S18]. No subscription or licensing revenue is disclosed.
Value-chain positionMid-stream processor and trader of red ginseng raw materials (2016–2023), then a downstream holder of industrial operating subsidiaries (2024–2026)
Customer typesB2B: large consumer-goods and cosmetics firms, pharmaceutical companies, food companies, shipyards and industrial buyers. Limited B2C through the STEMELIN cosmetics brand via home shopping [S27].
End-marketsKorean health functional foods, cosmetics, automotive parts, hydraulic machinery and heavy equipment parts, marine and ship components, fuel distribution
Revenue concentrationHigh. In FY2020, one product category (red ginseng raw materials) made up 81.76% of separate revenue [S18].

Strategy

Stated strategy (2021 IR, the last formal strategy statement found)

The May 2021 IR deck set out four strategic priorities [S18]:

  1. Expand health functional food raw-material sales, including a first-tier vendor contract with Ilyang Pharmaceutical.

  2. Pursue stem-cell value through affiliate MiraeCell Bio's planned KOSDAQ technology listing.

  3. Enter wound-dressing and IVD contract manufacturing via a GMP facility in the Gwangmyeong medical cluster.

  4. Maintain a no-borrowing financial stance.

None of these produced disclosed results. Bio-medical revenue collapsed by 2024 [S6]. No MiraeCell Bio listing was found in the sources reviewed. No GMP facility revenue was disclosed. Borrowings rose to about ₩24.9 billion by 2026 [S20].

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeTimingOutcome
Industrial diversification under CTM (CM Tech hydraulics, Gwangjin Sanjeon, fuel and ship-component trading)2024–2025Raised consolidated revenue in FY2024 but not profitability. Subject of embezzlement and breach-of-trust complaints [S16][S17].
Control sale to N Four Space / Oh Young-hoonJul–Dec 2024Failed for non-payment. The late disclosure triggered unfaithful-disclosure penalties [S14][S15].
₩1.0bn follow-on placement at ₩577 per shareFiled Dec 2024Small liquidity injection [S19]
Injunction against delistingAug 2025 – Jun 2026Delayed liquidation trading by about 10 months. Trading eventually resumed and the shares were delisted on 1 Jul 2026 [S1][S7].
ESG or sustainability programmes—None disclosed
Cost programmes with targets—None disclosed
Medium-term financial targets / guidance—None disclosed

Products & Services

The table covers every product or offering identifiable in public sources. BYON never published a priced catalogue. Specifications, launch years and pricing are given only where disclosed.

Bio-medical / health functional food raw materials

ProductDescriptionTarget customerLaunch / statusPricing
Red ginseng concentrate (홍삼농축액)Red ginseng processed from Geumsan ginseng with high-pressure technology. The company says the process reduces split roots and internal cavities and lowers defect rates.Large consumer-goods, cosmetics and pharmaceutical companies (Amorepacific and Ilyang Pharmaceutical named)Since Dec 2015—
Red ginseng powder (홍삼분말)Same process; powder formatSameSince Dec 2015—
Red ginseng slices (홍삼절편)Same process; sliced formatSameSince Dec 2015—
Secondary processed health productsHealth functional foods made from the above raw materials and supplied to customersB2BOngoing as of 2021—

Source: [S18]. The 2021 deck also refers to a first-tier vendor contract with Ilyang Pharmaceutical [S18].

Stem-cell and medical-device initiatives (largely through affiliate MiraeCell Bio)

ItemDescriptionStatus as last disclosedSource
MR-MC-01Embryonic-stem-cell-derived therapy for interstitial cystitis. Designated an orphan drug (No. 30) by MFDS. Described as a world-first Phase 1 approval in May 2020.Phase 1 / investigator studies ongoing (2021)[S18]
MMSCAllogeneic embryonic-stem-cell-derived mesenchymal stem-cell therapy platformClinical development funded by a ₩10 billion Pre-IPO round (Oct 2020)[S18]
Atopic dermatitis therapyPluripotent-stem-cell-based; clinical trial at Asan Medical CenterOngoing (2020–2021)[S18]
Human adipose stem-cell conditioned mediaCosmetic ingredient that meets MFDS standards. First listed in the International Cosmetic Ingredient Dictionary in 2010.Commercial ingredient[S18][S27]
Stem-cell-applied wound dressingsPlanned contract-manufacturing product for a GMP facility in the Gwangmyeong medical clusterPlanned (2021); no later commercialisation found[S18]
In-vitro diagnostic device contract manufacturingPlanned CMO servicePlanned (2021); no later commercialisation found[S18]
Cardiomyocyte commercialisationCited in third-party profiles as a stem-cell-based business objectiveNo product, approval or revenue disclosed[S13a][S26]

Affiliate IP cited by the company includes a US patent for a "dementia pig" model (Sept 2019), a Korean patent on mammoth-cell culture (Dec 2019), and stem-cell in-vivo tracking technology (Feb 2021) [S18]. These belong to MiraeCell Bio, not to BYON.

Cosmetics

ProductDescriptionChannelLaunch
STEMELIN (스템엘린) brandAnti-ageing cosmeceutical line built around stem-cell conditioned media, with collagen extract, elastin and hyaluronic acidHome shopping and onlineAug 2022 (home-shopping launch) [S27]
STEMELIN Hyper Active Cell AmpouleFlagship ampoule of the STEMELIN lineHome shoppingAug 2022 [S27]
Basic and colour cosmetics (merchandise)Traded cosmetics. Revenue ₩4.89 billion in FY2018, falling to ₩1.35 billion in FY2020.B2B / B2CPre-2018 [S18]
Cosmetic containers and auxiliary materialsCited in third-party profiles——

Industrial and other

Product lineDescriptionPeriodSource
Banner flexPlastic (PVC) advertising banner materialPolyvision era; still listed as the main product on some aggregators[S23]
Tarpaulins, PVC flooringIndustrial products; Ochang plant; flooring via subsidiary PolyfloorPolyvision era[S24][S18]
Auto parts (merchandise)Injection-moulded parts and seat fabricsUntil FY2019; minor in Q1 2021[S18]
Hydraulic motors / hydraulic machinery and partsThrough CM TechFrom 2024[S17][S25]
Ship componentsSegment cited in later filings2024–2025[S6][S25]
Fuel salesSegment cited in later filings; reported as a main 2025 revenue source2024–2025[S6][S25]
Beauty devices and furniture"Other" merchandise2018–2021[S18]

Financial Narrative

Data basis and caveats

Primary consolidated series: S&P Global Market Intelligence data as published by Simply Wall St, FY2015 to LTM Q1 2026 [S19]. Covers revenue, net income, G&A and R&D.

Company-reported series: the May 2021 IR deck, covering FY2019, FY2020 and Q1 2021 on both consolidated and separate bases [S18].

FY2025 separate figures: from the company's preliminary disclosure as reported by Topstarnews [S5] and iNews24 [S2].

Basis difference: FY2025 consolidated revenue was about ₩20.6 billion (S&P) [S19], but FY2025 separate revenue was ₩3.25 billion [S5]. Consolidated figures include CM Tech and the other 2024 acquisitions; separate figures are the listed parent alone. KRX listing tests (such as the ₩300 million quarterly revenue test) applied to the separate figure.

FY2025 is not audited in substance: because of the disclaimer of opinion [S2].

  • EPS, dividends per share, EBITDA, gross profit and operating income were not available for FY2021–FY2024 in the sources reviewed. Blank cells below mean not publicly disclosed / not available in the sources reviewed.

Income statement: consolidated

Sources: revenue, net income, G&A and R&D from [S19]. Margins and growth are computed. The FY2021 growth rate is against FY2020 revenue of ₩22,232 million [S18][S19]. Stockopedia confirms no dividend was paid [S25].

Revenue CAGR FY2021–FY2025 (consolidated): about 16.3%, matching Simply Wall St's reported 5-year revenue growth rate of 16.30% [S19]. The figure overstates operating health: the FY2024 jump came from acquired businesses, not organic growth.

Longer consolidated context

Sources: [S19]. Operating income for FY2019 and FY2020 is from the company IR deck [S18]. The IR deck shows consolidated net losses of ₩21,632 million (FY2019) and ₩6,404 million (FY2020) [S18], slightly different from the S&P figures (₩21,502 million and ₩6,365 million). The gap likely reflects attributable vs. total net income; both are shown.

Loss record: S&P data shows a consolidated net loss in every fiscal year from FY2015 through FY2025, eleven consecutive years [S19]. Asia Economy described six consecutive years of losses as of November 2023 [S8].

Separate (parent-only) income statement: notes and sources

Sources: FY2019–FY2020 from [S18]. FY2025 revenue (₩3,247,476,792) and operating loss (₩1,993,525,351) from [S5]. The FY2024 separate revenue of about ₩5,578 million is derived from the disclosed 41.79% FY2025 decline [S5]; it is not a reported figure.

Balance sheet: consolidated

Sources: FY2019, FY2020 and Q1 2021 from the company IR deck [S18]. Q1FY2026 from Simply Wall St (S&P) [S20], whose page is dated 30 June 2026 and uses earnings to 31 March 2026. Net debt and working capital are computed. FY2021–FY2025 year-end balance sheets were not available in the sources reviewed.

FY2025 separate liquidity points (iNews24) [S2]:

  • Current assets of about ₩5.1 billion, roughly half the prior year.

  • Current liabilities of about ₩14.4 billion.

  • Cash and equivalents of about ₩150 million, down about 80%.

  • A ₩1.8 billion short-term financial instrument position fully liquidated.

THE VC reports that the separate current ratio fell from 359.8% (FY2023) to 19.3% (FY2024) [S23].

Cash flow: notes and sources

Source: [S18]. Capex, dividends paid and buybacks were not separately disclosed. No dividends or buybacks are recorded. Simply Wall St flagged trailing free cash flow of about −₩3.2 billion in late 2024 and less than one year of cash runway [S20].

Ratios

Sources: FY2019–FY2020 ratios from [S18], with debt/equity computed from 6.5. Q1FY2026 ROE, net margin and debt/equity from [S19][S20]; current ratio and liabilities/equity computed. ROA, ROIC, interest coverage (n/a on negative EBIT [S20]), asset turnover and cash conversion cycle cannot be computed reliably from the available data.

Commentary on trends, inflections and drivers

FY2019 → FY2020: the only real inflection. COVID-era demand for immunity products lifted red-ginseng raw-material sales; bio-medical segment revenue rose about 94% to ₩12.8 billion [S18]. BYON also exited cosmetics manufacturing, which had been a margin drag, and recovered a long-overdue receivable from its Beijing associate. Together these moved the consolidated operating loss from −₩10.3 billion to −₩0.55 billion and produced a separate operating profit of ₩2.68 billion [S18]. Borrowings fell from ₩21.3 billion to ₩4.7 billion after collateralised assets were sold and convertible bonds were converted or repurchased [S18]. This is the period management presented as a stable, "no-borrowing" balance sheet.

FY2021 → FY2023: erosion. Consolidated revenue roughly halved in FY2021 to ₩11.2 billion and fell to ₩8.9 billion by FY2023 [S19]. Net losses continued at ₩7–13 billion a year. G&A expense rose from ₩6.0 billion to ₩7.3 billion while revenue shrank, taking G&A to 82% of revenue in FY2023. Funding came mainly from equity and convertible-bond issuance, including the ₩8.0 billion 39th CB in June 2021 and roughly ₩1.0 billion follow-on placements. Simply Wall St recorded 8.5–19% annual shareholder dilution in this period [S19][S20].

FY2024: acquisition-driven revenue spike, no profit improvement. Revenue tripled to ₩27.0 billion after the purchase of CM Tech and the start of fuel and ship-component trading, but the net loss widened to ₩8.9 billion and G&A rose to ₩10.1 billion [S19]. The acquisitions were funded with convertible bonds (₩10.5 billion 41st series; ₩10.0 billion 42nd series) whose validity was challenged in court in September 2024 [S13]. The separate current ratio fell from 359.8% to 19.3% [S23]. The parent's liquidity effectively disappeared as cash moved into related-party and acquisition assets.

FY2025 → Q1 2026: terminal phase. Consolidated revenue fell 24% to ₩20.6 billion, with a net loss of ₩6.6 billion [S19]. Parent-only revenue fell 41.79% to ₩3.25 billion [S5]. Cash at the parent was about ₩150 million [S2]. On a consolidated basis, total borrowings of about ₩24.9 billion against equity of ₩16.3 billion gave debt/equity of 152.5%, up from about 15% five years earlier [S20]. LTM revenue to March 2026 fell further to ₩11.9 billion [S19]. The auditor's going-concern disclaimer [S2] is consistent with these numbers.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContents (company description)Revenue type

Bio-medical (바이오의료)

Health-food raw materials, mainly red ginseng concentrate, powder and slices made with high-pressure processing. Also includes stem-cell-related affiliate holdings (MiraeCell Bio) and the planned GMP medical-device project.

Merchandise

Cosmetics (화장품)

Basic and colour cosmetics. Cosmetics manufacturing was being wound down by 2020 to improve margins.

Merchandise

Auto parts (자동차부품)

Injection-moulded parts and seat fabrics

Merchandise

Other (기타)

Beauty devices, furniture and similar

Merchandise

Revenue by Segment

SegmentFY2018FY2019FY2020

Bio-medical revenue (KRW Mn)

8,0806,58612,809

Cosmetics revenue (KRW Mn)

4,8942,2751,345

Auto parts revenue (KRW Mn)

2,7841,2170

Other revenue (KRW Mn)

7513161,513

Total separate segment revenue (KRW Mn)

16,50910,39415,667

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (%) and Segment Margins & Growth (%)

MetricFY2018FY2019FY2020

Bio-medical share of revenue (%)

48.9463.3681.76

Cosmetics share of revenue (%)

29.6421.898.58

Auto parts share of revenue (%)

16.8611.710

Other share of revenue (%)

4.553.049.66

Bio-medical YoY growth (%)

—-18.594.5

Cosmetics YoY growth (%)

—-53.5-40.9

Auto parts YoY growth (%)

—-56.3-100.0

Revenue by Segment (FY2021–FY2024)

SegmentFY2021FY2024

Bio-medical revenue (KRW Mn)

9,600200

Group Entities

EntityRelationshipStake (%)

Polyfloor Co., Ltd. (폴리플로어)

Subsidiary (legacy flooring business)

81.37

MiraeCell Bio Co., Ltd. (미래셀바이오)

Associate; stem-cell therapies

23.53

Beijing company (북경원일차식유한공사), China

Associate

47.00

Gwangmyeong Hana BYON (광명하나바이온)

Associate

14.00

BYON Meditech Co., Ltd. (바이온메디테크)

Subsidiary

100.00

K-Star Entertainment (케이스타엔터테인먼트)

Associate

42.86

Anti-Aging Co., Ltd., Japan (안티에이징)

Associate

50.00

BYON Global Co., Ltd. (바이온글로벌)

Subsidiary

100.00

Group Entities — Gwangjin Sanjeon

EntityBusinessStake / costDate

Gwangjin Sanjeon (광진산전)

Industrial operating company; specific product line not disclosed in the sources reviewed

28% for ₩6.02 billion

7 Mar 2024

CM Tech (씨엠텍)

Heavy-equipment parts and hydraulic machinery and parts manufacturing

100% for ₩11.0 billion

2024, after the 41st CB in May

GN Equity (지엔에쿼티)

Real-estate leasing and trading, newly established

₩1.5 billion capital contribution

4 Jul 2024

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Mn)

11,23912,8778,88926,95620,596

Revenue YoY growth (%)

-49.414.6-31.0203.3-23.6

Net income (KRW Mn)

-13,361-9,793-6,978-8,851-6,606

G&A expense (KRW Mn)

5,9996,7117,29710,0956,208

R&D expense (KRW Mn)

3023825964421

Net margin (%)

-118.9-76.1-78.5-32.8-32.1

G&A as % of revenue (%)

53.452.182.137.430.1

Dividends per share (KRW)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricFY2016FY2017FY2018FY2019FY2020

Revenue (KRW Mn)

23,19918,14635,04719,62422,232

Net income (KRW Mn)

-2,057-5,369-10,492-21,502-6,365

Operating income (KRW Mn)

———-10,293-553

Income Statement and Margin Analysis (%) (FY2019–FY2025)

MetricFY2019FY2020FY2024FY2025

Revenue (KRW Mn)

10,40815,6675,5783,247

Operating income (KRW Mn)

-4,7042,680—-1,994

Net income (KRW Mn)

-18,172-11,176——

Operating margin (%)

-45.217.1—-61.4

Balance Sheet

MetricFY2019FY2020Q1FY2021Q1FY2026

Total assets (KRW Mn)

61,43846,35947,36752,490

Current assets (KRW Mn)

23,99820,38219,8026,100

Cash and equivalents (KRW Mn)

5,55414,07910,346104

Total liabilities (KRW Mn)

27,0517,4448,92736,170

Current liabilities (KRW Mn)

17,8635,8585,86515,200

Non-current liabilities (KRW Mn)

9,1881,5853,06121,000

Total borrowings incl. CBs and leases (KRW Mn)

21,2874,7206,35624,900

Short-term borrowings (KRW Mn)

1,0811,0421,000—

Long-term borrowings (KRW Mn)

4,95901,380—

Convertible bonds (KRW Mn)

14,2443,3203,468—

Net debt (KRW Mn)

15,733-9,359-3,99024,796

Total equity (KRW Mn)

34,38738,91538,44016,330

Intangible assets (KRW Mn)

2,72731553—

Investments in subsidiaries and associates (KRW Mn)

14,05516,29616,393—

Working capital (KRW Mn)

6,13514,52413,937-9,100

Cash Flow

MetricFY2019FY2020Q1FY2021

Operating cash flow, consolidated (KRW Mn)

-2,5563,110-2,727

Investing cash flow, consolidated (KRW Mn)

-2,52110,937-3,152

Financing cash flow, consolidated (KRW Mn)

4,956-5,6502,146

Operating cash flow, separate (KRW Mn)

-1,1164,579-2,447

Margin Analysis (%)

RatioFY2019FY2020Q1FY2026

Current ratio, consolidated (%)

134.35347.9040.1

Liabilities / equity, consolidated (%)

78.6719.13221.5

Debt / equity (%)

61.912.1152.5

Return on equity (%)

——-34.47

Net margin (%)

——-50.78

Share Price History

DatePrice (KRW)Context

10 Jul 2020

992

Pre-COVID-rally reference

4 Nov 2020

1,955

90-day high during the red-ginseng demand surge

10 Mar 2021

1,270

90-day low

Date not specified

1,118

Stockopedia reference; −14.25% over the preceding 365 days

12 Nov 2023

~1393

Implied: the CTM average price of ₩3,344 was described as 140% above the prior close

Jul 2024

1,185

Price at the July 2024 control-transfer contract

27 Feb 2025

604

−73.08% over the preceding 365 days

25 Jun 2026

16

Liquidation trading

26 Jun 2026

8

Liquidation trading

29 Jun 2026

5

Liquidation trading

30 Jun 2026

2

Final trade before delisting

Valuation Snapshot

MetricValue

1-year return to 27 Feb 2025

−73.08% [S11a]

H1 2026 return

−99.67%, the worst on KOSDAQ [S29]

3-year and 5-year total return

Not computed precisely. From roughly ₩1,270–1,955 (2020–2021) to ₩2 (June 2026), the loss is effectively 99.9%. Interim share consolidation (see 9.4) may make unadjusted comparisons inexact.

Valuation Snapshot by Multiple

MultipleValueNote

P/E

n/m (negative earnings)

Stockhub showed −2.16 TTM, on stale data [S28]

EV/EBITDA

n/m

EBITDA negative or undisclosed

EV/Sales

~1.2x

Computed: about ₩24.8bn net debt plus ₩60.8m market cap at delisting, against LTM revenue of ₩11.9bn. Indicative only.

P/B

~0.00x at delisting

Market cap ₩60.8m vs. book equity ₩16.3bn [S19][S20]

Peer multiples

Not compiled

—

Capital Markets

ItemStatus

Dividend history

No dividends paid [S25]

Dividend policy

None disclosed

Buyback authorisations

None disclosed

Credit ratings (Moody's, S&P, Fitch)

Not rated

Analyst consensus

None (0 analysts) [S19]

Capital Instruments

InstrumentIssue dateAmount (KRW)Conversion price (KRW)Status

37th CB

Before 2021

1500000000 outstanding at Q1 2021

——

38th EB

Before 2021

3000000000 outstanding at Q1 2021

——

39th CB

4 Jun 2021

8,000,000,000

1392 at issue; 892 at June 2024 conversion

₩3.8bn converted June 2024 (4,260,086 shares); originally maturing 4 Jun 2024

40th CB

—1,500,000,000—

Convertible from March 2024 into 1,335,707 shares

41st CB

16 May 2024

10,500,000,000898

Validity challenged (Sept 2024 suit)

42nd CB

202410,000,000,000—

Validity challenged (Sept 2024 suit)

Third-party allotment

8 Apr 2021

~5000000000

~1215 implied (₩5.0bn / 4,115,226 shares)

Completed

Third-party allotment (CTM)

Nov 2023

7,000,000,0001,231

Completed

Follow-on placements

2020–2024

~1000000000 each

1260; 1430; 1146; 577

Completed

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance

None. BYON issued no financial guidance in the period reviewed. After delisting, it has no exchange-disclosure obligation, and no post-delisting corporate communication was found as of 16 October 2026.

Consensus expectations

None. There is no analyst coverage [S19].

Bull-case arguments (grounded, with low probability)

  1. Residual asset value. Consolidated book equity was about ₩16.3bn at Q1 2026 [S20], including 100% of CM Tech (bought for ₩11.0bn) and 28% of Gwangjin Sanjeon (₩6.02bn) [S17][S10]. If these assets are realisable near cost, shareholders of the now-unlisted company hold a claim worth far more than the ₩60.8m market value at delisting.

  2. Operating subsidiaries still generate revenue. LTM consolidated revenue to March 2026 was ₩11.9bn [S19]. Pharmatimes reported positive cumulative operating profit (about ₩0.4bn) through 3Q 2025 at the consolidated level [S6], so the operating subsidiaries are not necessarily loss-making on their own.

  3. Legal recoveries. If the complaints over Gwangjin Sanjeon (₩6bn) and GN Equity (₩1.5bn) succeed, they could support civil recovery for the company [S12][S16].

Bear-case arguments

  1. Equity is effectively stranded. Delisted shares lose market liquidity, and the final traded price of ₩2 [S28] reflects the market's view of recoverable value.

  2. Book values are unreliable. The FY2025 disclaimer means asset carrying values, including the related-party acquisitions, have not been validated by an auditor [S2]. The complaint alleges the Gwangjin Sanjeon valuation was inflated by about ₩7.2bn above a 2022 reference [S16].

  3. Creditors rank first. Total liabilities of ₩36.2bn exceed total assets less any impairment, with current liabilities about 2.5 times current assets [S20]. In any restructuring, CB holders and lenders, including holders of disputed CBs, rank ahead of equity.

Catalysts and monitorables (next 12 months)

ItemWhy it matters
Outcome of the injunction and any merits suit against KRXRelisting after execution of delisting would be highly unusual; confirms finality
Prosecutorial decisions on the three criminal complaintsPossible indictments; potential civil recovery
Rulings on CB validity (41st and 42nd series)Determines the liability structure
Any insolvency, rehabilitation or sale filing by BYON or CTMDetermines recovery for residual equity
Status of CM Tech and Gwangjin Sanjeon (sale or retention)Main value-bearing assets
FY2026 audit (if any)A going-concern assessment would indicate survivability

Analyst verdict

BYON Co., Ltd. no longer has an investment case as a listed equity. It was delisted from KOSDAQ on 1 July 2026 after a final liquidation-trading window in which the shares fell to ₩2 [S1][S28]. The forensic lesson is more useful than any valuation.

Across four decades the company changed name five times and changed its business model at least four times. Each pivot coincided with a change of controlling shareholder rather than with a market opportunity it was equipped to capture. Its "bio" identity rested on a red-ginseng trading business that briefly benefited from COVID-era demand: FY2020 was the only year with a separate operating profit (₩2.68bn) [S18]. The identity also rested on a minority stake in someone else's stem-cell pipeline, while BYON's own R&D never exceeded about 3% of revenue [S19].

After CTM took control in late 2023, the company bought assets connected to its new owner. It funded them with convertible bonds that were later challenged in court, and it failed to disclose a control-transfer contract on time. Insiders filed three criminal complaints against management within two months [S12][S16][S17]. The exchange then removed the company on continuity and transparency grounds. A going-concern audit disclaimer [S2] and revenue below the KOSDAQ threshold [S4][S5] meant there were three independent paths to delisting by mid-2026.

For an analyst, BYON shows the pattern behind the KOSDAQ "zombie company" problem that drove the 2025–2026 reforms. Its warning signs were visible in the data years before the outcome: persistent losses, heavy reliance on CB financing, frequent control trades at large premiums to market, related-party asset purchases, and very small headcount. Residual value for former shareholders, if any, depends on asset realisation and legal recoveries outside the public market, and it ranks behind creditors.

Rating: Not rateable (delisted). Residual equity: speculative, with high risk of total loss.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure (as of Jun 2026)BackgroundAge

Ryu Jin-hyung (류진형)

CEO and Representative Director

Since 23 Jan 2024 (2.4 yrs)

CEO of Central Holdings; former CEO of Jungang Ocean Co., Ltd. [S21]. Asia Economy describes him as a former senior managing director of CTM [S16].

58

Jang Young-ho (장영호)

Representative Director

~1.8 yrs

——

Jeong Min-ho (정민호)

Inside Director

~2.4 yrs

——

Seo Dong-il (서동일)

Inside Director (listed by S&P); a Jan 2025 EGM agenda sought his removal

~1.8 yrs

Filed three criminal complaints against management

—

Jeong Haeng-ju (정행주)

Independent Outside Director

~2.4 yrs

——

Oh Byeong-hoon (오병훈)

Independent Outside Director

~1.8 yrs

——

Choi Yong-seok (최용석)

Statutory Auditor

~2.4 yrs

Named as a respondent in the Dec 2024 complaint

—

Lee Soo-yeon (이수연)

Statutory Auditor

~1.8 yrs

Co-filed the Dec 2024 complaint against the CEO

—

“—” = not publicly disclosed.

Executive Leadership Team

NameRolePeriod

Lee Sung-min (이성민)

Former CEO; later associated with deals at Yujient and Jungang Ocean

To 2016

Kim Byung-joon (김병준)

CEO

2016 – Jan 2024; also a selling shareholder in the 2023 CTM transaction

Park Beom-jin (박범진), Park Jeong-han (박정한)

Listed as representatives on THE VC (date of service not confirmed)

Not confirmed

Major Shareholders

DateHolderSharesStake (%)

Apr 2021

W Global No.1 Union (largest shareholder; its own largest holder is Oncotrack and 2 others)

6,603,1889.87

Apr 2021

Lee Jin-woong (related party)

1,396,0892.09

Apr 2021

Total shares outstanding

66,900,777100.00

Nov 2023

W Global No.1 Union + Kim Byung-joon (sold to CTM)

3,560,4369.37

Early 2024

CTM after share purchase and ₩7.0bn allotment

—17.55

Jul 2024

CTM (entire holding under transfer contract)

3,560,4367.95

“—” = not publicly disclosed.

Competitive Landscape

Competitors by Segment

SegmentRepresentative competitorsBYON's relative position

Red ginseng and health-food raw materials

Korea Ginseng Corp. (KT&G group); other ginseng processors and contract health-food manufacturers

Small trader-processor using partner farm supply and partner processing technology. Customer list included large buyers, but revenue peaked at ₩12.8bn in FY2020.

Stem-cell therapies (via affiliate)

Pharmicell, Medipost, Anterogen, Corestem (Korean stem-cell developers)

Minority investor only; no approved product

Stem-cell-ingredient cosmetics

Numerous Korean cosmeceutical brands and ODM makers

STEMELIN was a niche home-shopping brand; cosmetics revenue was ₩1.35bn in FY2020

Hydraulic machinery and heavy-equipment parts (CM Tech)

Korean hydraulic component makers serving the construction-equipment industry

Newly acquired subsidiary; no market share disclosed

Ship components

Large pool of Gyeongsang-region shipbuilding suppliers

Trading presence; scale not disclosed

Fuel sales

Refiners' distribution networks and independent distributors

Commodity trading; low margin

Legacy PVC banners and flooring

Building-materials and film producers

Exited

Peer Comparison FY2025

MetricBYON (FY2025, consolidated)Peer comparison

Revenue

₩20.6bn [S19]

—

Revenue growth

−23.6%

Not compiled

Net margin

−32.1%

Not compiled

R&D intensity

0.10%

Not compiled

Recent Developments

Earlier items from the build-up (Dec 2024 – Mar 2025) are included for context and marked.

Company Snapshot

$14.5M

Revenue

17

Employees

1983

Founded

SWOT Analysis

Strengths

  • Long corporate history and listing tenure. Founded 1983 and listed on KOSDAQ for about 29 years (Aug 1997 – Jul 2026), which gave access to public capital through repeated placements and CBs [S18][S1].
  • Large-customer relationships in red ginseng. Supplied raw materials to Amorepacific and Ilyang Pharmaceutical [S18].
  • Demonstrated ability to turn a separate operating profit (FY2020). Separate operating income of ₩2.68bn and a 17.1% margin when demand aligned [S18].
  • Low leverage at FY2020. Liabilities/equity of 19.13% and cash of ₩14.1bn (consolidated) [S18].
  • Stem-cell ingredient access. MiraeCell Bio's adipose stem-cell conditioned media was ICID-listed and meets MFDS cosmetic standards, supporting the STEMELIN brand [S18][S27].
  • Diversified segment exposure after 2024. Eight reporting segments reduced dependence on a single product line, although at low margins [S25].

Weaknesses

  • Eleven consecutive years of consolidated net losses (FY2015–FY2025) [S19].
  • Minimal R&D: 0.10% of revenue in FY2025 and never above ₩1.12bn a year [S19].
  • Parent liquidity collapse: separate cash of about ₩150m and current liabilities of ₩14.4bn against current assets of ₩5.1bn in FY2025 [S2].
  • Revenue below listing thresholds: FY2025 separate revenue of ₩3.25bn and quarterly revenue under ₩300m [S5][S4].
  • Weak board: 2 of 6 directors independent; no director with more than about 2.4 years of tenure [S21].
  • Rising leverage: debt/equity rose from about 15% to 152.5% over five years [S20].

Opportunities

  • Growth in the Korean health functional food market, cited at about ₩4.9tn in 2019 [S18].
  • A potential MiraeCell Bio listing, which could have revalued BYON's 23.53% stake [S18].
  • Contract manufacturing of wound dressings and IVD devices at a Gwangmyeong GMP site [S18].
  • The Ilyang Pharmaceutical first-tier vendor contract as a base for volume growth [S18].
  • A credible new controlling shareholder recapitalising the company. Three such attempts in 2023–2024 failed or ended in dispute [S8][S15].
  • The post-delisting option of operating as an unlisted company.

Threats

  • Delisting, now realised on 1 Jul 2026 [S1].
  • Criminal and civil exposure: three complaints against management and the largest shareholder alleging embezzlement, breach of trust and Capital Markets Act fraud [S12][S16][S17].
  • CB validity litigation: a September 2024 suit sought to invalidate the 41st (₩10.5bn) and 42nd (₩10.0bn) CB issues [S13].
  • Going-concern doubt stated by the auditor [S2].
  • Creditor actions against the controlling shareholder: a ₩3.55bn provisional attachment on CTM's Ansan plant [S13].
  • Tightened regulatory regime for distressed KOSDAQ issuers, with the KRX running an intensive delisting-management period from February 2026 to June 2027 [S30].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
31 Dec 2024 (context)Statutory auditor Lee Soo-yeon and inside director Seo Dong-il file a complaint at Gangnam Police Station against CEO Ryu, director Jeong Min-ho, outside director Jeong Haeng-ju, auditor Choi Yong-seok and the GN Equity CEO, alleging embezzlement and breach of trust over the ₩1.5bn GN Equity investment [S12]Board split; governance failure
31 Dec 2024 (context)Follow-on placement of ₩1.0bn (1,733,101 shares at ₩577) filed [S19]Emergency liquidity
Jan 2025 (context)Ansan branch of Suwon District Court approves N Four Space's ₩3.55bn provisional attachment on CTM's Ansan plant [S13]Controlling shareholder under creditor pressure
16 Jan 2025 (context)EGM scheduled to remove director Seo and amend the articles [S12]Management consolidates control
4–5 Feb 2025 (context)After a KRX inquiry, BYON discloses that a July 2024 control-transfer contract was signed and cancelled without timely disclosure [S14][S15]Disclosure violation
18–19 Feb 2025 (context)Seo files a ₩6bn embezzlement and breach-of-trust complaint with Seoul Southern District Prosecutors over the Gwangjin Sanjeon purchase. KRX gives advance notice of unfaithful-disclosure designation (2 non-disclosures, 1 reversal). [S16]Legal and listing risk escalates
26–27 Feb 2025 (context)Third complaint, alleging Capital Markets Act fraud and breach of trust over CB issuance and the CM Tech acquisition [S17]Third criminal complaint
27 Feb 2025Share price ₩604; market cap about ₩13.5bn [S13a]Pre-collapse reference point
31 Mar 2025FY2024 AGM (Gwacheon) [S19]Routine
May 2025Unfaithful-disclosure designation: cumulative 18 penalty points, triggering a listing-eligibility review [S6]Delisting pathway opens
Jul 2025Disclosure of a management-change contract adds further review grounds; board registry changes (several resignations and appointments on 30 Jul 2025) [S6][S23]Further instability
21 Aug 2025KOSDAQ decides to delist BYON [S4]Decisive event
22 Aug 2025Injunction filed at Seoul Southern District Court; liquidation trading suspended pending the ruling [S7]Temporary reprieve
16–17 Oct 2025Board registry changes (appointment and resignation) [S23]Ongoing turnover
Dec 2025NPS-registered headcount shown as 0 [S23]Operational hollowing
14 Jan 2026Pharmatimes lists BYON among 5 pharma/bio names whose delisting was decided in 2025, all held up by injunctions [S6]Sector context
Feb–Mar 2026Preliminary FY2025 disclosure: separate revenue ₩3.25bn (−41.79%), operating loss ₩1.99bn; quarterly revenue below ₩300m creates administrative-issue and review triggers [S5]Business fails core listing tests
31 Mar 2026FY2025 AGM (Ansan) [S19]Routine
8 Apr 2026FY2025 audit: disclaimer of opinion on going-concern grounds; formal delisting cause [S2]Second, independent delisting cause
9 Apr 2026KRX annual review: BYON among the KOSDAQ names already slated for delisting, so no new improvement period applies [S3]Removal confirmed
15 May 2026Discloses Q1 2026 revenue below ₩300m ("suspension of main business" test); KRX says next steps depend on the litigation outcome [S4]Third delisting cause
18 Jun 2026KRX announces liquidation trading from 22 to 30 Jun 2026 and delisting on 1 Jul 2026, implying the injunction no longer blocked removal (the court ruling itself was not found in the sources reviewed) [S1]Final notice
24–29 Jun 2026Liquidation trading: the share price falls in steps (₩16 on 25 Jun, ₩8 on 26 Jun, ₩5 on 29 Jun) [S29]Value wipe-out
30 Jun 2026Last trading day; final price ₩2 [S28]—
1 Jul 2026Delisted from KOSDAQ [S1]Listing ends
6 Jul 2026Reported as the worst KOSDAQ performer of H1 2026 at −99.67% [S29]Market record

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (FY2018–FY2020): Total separate segment revenue fell from KRW 16,509 Mn in FY2018 to KRW 15,667 Mn in FY2020.
BYON Co., Ltd. — Revenue by Segment (FY2018–FY2020)
Series (KRW Mn)FY2018FY2019FY2020
Total separate segment revenue16,50910,39415,667
Bio-medical revenue8,0806,58612,809
Cosmetics revenue4,8942,2751,345
Auto parts revenue2,7841,2170
Other revenue7513161,513

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1Topstarnews: BYON liquidation trading notice (22–30 Jun 2026; delisting 1 Jul 2026) — 18 Jun 2026 (topstarnews.net)
  2. S2iNews24 via Daum: "'상폐 위기' 바이온, 또 '의견거절'" (FY2025 disclaimer, liquidity data) — 8 Apr 2026 (v.daum.net)
  3. S3iNews24: 16 KOSDAQ delistings confirmed; BYON among names already slated for delisting — 9 Apr 2026 (inews24.com)
  4. S4Topstarnews: Q1 2026 revenue below ₩300m; delisting decision of 21 Aug 2025; injunction pending — May 2026 (topstarnews.net)
  5. S5Topstarnews: preliminary FY2025 separate results (revenue ₩3.247bn, −41.79%; operating loss ₩1.994bn) — ~Feb 2026 (topstarnews.net)
  6. S6Pharmatimes: 2025 listing-eligibility reviews in pharma/bio; BYON penalty points, segment shift — 14 Jan 2026 (pharmatimes.co.kr)
  7. S7Edaily: BYON files injunction against KRX delisting decision — 22 Aug 2025 (edaily.co.kr)
  8. S8Asia Economy: [기로의상장사] 바이온 ① (CTM sale, failed I-World Pharm deal) — 14 Nov 2023 (core.asiae.co.kr)
  9. S9Asia Economy: [기로의상장사] 바이온 ② (CTM ownership, prior management) — 16 Nov 2023 (core.asiae.co.kr)
  10. S10Asia Economy: [기로의상장사] 바이온 ③ (Gwangjin Sanjeon 28% for ₩6.02bn) — 14 Mar 2024 (view.asiae.co.kr)
  11. S11Asia Economy: [기로의상장사] 바이온 ④ (39th CB conversion, overhang) — 5 Jun 2024 (core.asiae.co.kr)
  12. S11aStockopedia: ByOn Co share price page (₩604; −73.08% 1-yr) — 2025 (stockopedia.com)
  13. S12Asia Economy: auditor and director file complaint against CEO Ryu (GN Equity) — 3 Jan 2025 (core.asiae.co.kr)
  14. S13Asia Economy: provisional attachment on CTM's property; CB invalidation suit — 17 Jan 2025 (core.asiae.co.kr)
  15. S13aSimply Wall St: BYON stock page (market cap ₩13.5bn, price ₩604, 14 employees, CEO) — 2025 (simplywall.st)
  16. S14Asia Economy: undisclosed control-transfer contract; KRX investigating — 4 Feb 2025 (core.asiae.co.kr)
  17. S15Smarttoday: BYON confirms undisclosed M&A contract (signed Jul 2024, cancelled Dec 2024) — 5 Feb 2025 (smarttoday.co.kr)
  18. S16Asia Economy: CEO Ryu accused of ₩6bn embezzlement and breach of trust (Gwangjin Sanjeon) — 18–19 Feb 2025 (core.asiae.co.kr)
  19. S17Asia Economy: third complaint, Capital Markets Act (CB issuance, CM Tech acquisition) — 26–27 Feb 2025 (core.asiae.co.kr)
  20. S18BYON Co., Ltd. IR presentation (company overview, segments, financials FY2018–Q1 2021) — 27 May 2021 (file.alphasquare.co.kr)
  21. S19Simply Wall St (S&P Global Market Intelligence data): Past performance, revenue and earnings history, announcements — Data to 30 Jun 2026 (simplywall.st)
  22. S20Simply Wall St: Balance sheet and financial health — Data to 30 Jun 2026 (simplywall.st)
  23. S21Simply Wall St: Management and board — Data to 30 Jun 2026 (simplywall.st)
  24. S22Simply Wall St: Company information (founded 1983; listing Sep 2000; Ochang address) — 2025 (simplywall.st)
  25. S23THE VC: BYON profile (name history, address, headcount, registry events) — Accessed Oct 2026 (thevc.kr)
  26. S24EMIS: BYON Co., Ltd. company profile (Polyvision products, name change) — Updated Jul 2024 (emis.cn)
  27. S25Stockopedia: ByOn Co profile (segments, no dividend) — 2025–2026 (stockopedia.com)
  28. S26Morningstar Australia: Byon Co Ltd company profile (Seoul address, 15 employees) — 2025 (morningstar.com.au)
  29. S27Etoday: BYON launches STEMELIN on home shopping — 25 Aug 2022 (etoday.co.kr)
  30. S28StockHub: BYON quote page (liquidation trading, final ₩2) — Jun–Jul 2026 (stockhub.kr)
  31. S29Seoul Shinmun and Newdaily, as indexed on THE VC news feed (liquidation-period prices; H1 2026 −99.67%) — 24 Jun – 6 Jul 2026 (thevc.kr)
  32. S30Financial Services Commission: measures to strengthen delisting rules; Korea Times coverage — 12 Feb 2026 · koreatimes.co.kr
  33. S31MTN: KOSDAQ penalty-point threshold lowered to 10 from 1 July 2026 — 3 Jul 2026 (news.mtn.co.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.